Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Triad Technology Building, 333 Cassell Drive, Baltimore, MD, 21224, USA.
Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, Diagonal 643, 08028, Barcelona, Spain.
Mol Neurobiol. 2018 Nov;55(11):8438-8454. doi: 10.1007/s12035-018-1004-1. Epub 2018 Mar 18.
The poor norepinephrine innervation and high density of Gi/o-coupled α- and α-adrenoceptors in the striatum and the dense striatal dopamine innervation have prompted the possibility that dopamine could be an effective adrenoceptor ligand. Nevertheless, the reported adrenoceptor agonistic properties of dopamine are still inconclusive. In this study, we analyzed the binding of norepinephrine, dopamine, and several compounds reported as selective dopamine D-like receptor ligands, such as the D receptor agonist 7-OH-PIPAT and the D receptor agonist RO-105824, to α-adrenoceptors in cortical and striatal tissue, which express α-adrenoceptors and both α- and α-adrenoceptors, respectively. The affinity of dopamine for α-adrenoceptors was found to be similar to that for D-like and D-like receptors. Moreover, the exogenous dopamine receptor ligands also showed high affinity for α- and α-adrenoceptors. Their ability to activate Gi/o proteins through α- and α-adrenoceptors was also analyzed in transfected cells with bioluminescent resonance energy transfer techniques. The relative ligand potencies and efficacies were dependent on the Gi/o protein subtype. Furthermore, dopamine binding to α-adrenoceptors was functional, inducing changes in dynamic mass redistribution, adenylyl cyclase activity, and ERK1/2 phosphorylation. Binding events were further studied with computer modeling of ligand docking. Docking of dopamine at α- and α-adrenoceptors was nearly identical to its binding to the crystallized D receptor. Therefore, we provide conclusive evidence that α- and α-adrenoceptors are functional receptors for norepinephrine, dopamine, and other previously assumed selective D-like receptor ligands, which calls for revisiting previous studies with those ligands.
纹状体中去甲肾上腺素神经支配不良和 Gi/o 偶联的α-和α-肾上腺素能受体密度高,以及纹状体中多巴胺神经支配密集,这促使人们认为多巴胺可能是一种有效的肾上腺素能受体配体。然而,多巴胺的报道的肾上腺素能激动特性仍然不确定。在这项研究中,我们分析了去甲肾上腺素、多巴胺和一些被报道为选择性多巴胺 D 样受体配体的化合物,如 D 受体激动剂 7-OH-PIPAT 和 D 受体激动剂 RO-105824,与皮质和纹状体组织中α-肾上腺素能受体的结合,这些组织分别表达α-肾上腺素能受体和α-和α-肾上腺素能受体。发现多巴胺与α-肾上腺素能受体的亲和力类似于 D 样和 D 样受体。此外,外源性多巴胺受体配体也对α-和α-肾上腺素能受体表现出高亲和力。还通过生物发光共振能量转移技术分析了它们通过α-和α-肾上腺素能受体激活 Gi/o 蛋白的能力。相对配体效力和效率取决于 Gi/o 蛋白亚型。此外,多巴胺与α-肾上腺素能受体的结合是功能性的,可诱导动态质量重分布、腺苷酸环化酶活性和 ERK1/2 磷酸化的变化。通过计算机配体对接模拟进一步研究了结合事件。多巴胺在α-和α-肾上腺素能受体上的对接几乎与其与结晶 D 受体的结合相同。因此,我们提供了确凿的证据表明α-和α-肾上腺素能受体是去甲肾上腺素、多巴胺和其他以前假定的选择性 D 样受体配体的功能性受体,这需要重新审视以前使用这些配体的研究。